1570|0|Public
5|$|Bacterial infections may {{be treated}} with antibiotics, which are {{classified}} as bacteriocidal if they kill bacteria, or bacteriostatic if they just prevent bacterial growth. There are many types of antibiotics and each class inhibits {{a process that is}} different in the pathogen from that found in the host. An example of how antibiotics produce selective toxicity are chloramphenicol and <b>puromycin,</b> which inhibit the bacterial ribosome, but not the structurally different eukaryotic ribosome. Antibiotics are used both in treating human disease and in intensive farming to promote animal growth, where they may be contributing to the rapid development of antibiotic resistance in bacterial populations. Infections can be prevented by antiseptic measures such as sterilising the skin prior to piercing it with the needle of a syringe, and by proper care of indwelling catheters. Surgical and dental instruments are also sterilised to prevent contamination by bacteria. Disinfectants such as bleach are used to kill bacteria or other pathogens on surfaces to prevent contamination and further reduce the risk of infection.|$|E
25|$|A {{number of}} {{antibiotics}} act by inhibiting translation. These include anisomycin, cycloheximide, chloramphenicol, tetracycline, streptomycin, erythromycin, and <b>puromycin.</b> Prokaryotic ribosomes {{have a different}} structure from that of eukaryotic ribosomes, and thus antibiotics can specifically target bacterial infections without any harm to a eukaryotic host's cells.|$|E
25|$|Oxytocin {{is known}} to be metabolized by the oxytocinase, leucyl/cystinyl aminopeptidase. Other oxytocinases are also known to exist. Amastatin, bestatin (ubenimex), leupeptin, and <b>puromycin</b> have been found to inhibit the enzymatic {{degradation}} of oxytocin, though they also inhibit the degradation of various other peptides, such as vasopressin, met-enkephalin, and dynorphin A.|$|E
25|$|When {{functional}} proteins {{have been}} isolated, {{it is necessary}} that their genes are too, therefore a genotype-phenotype link is required. This can be covalent, such as mRNA display where the mRNA gene is linked to the protein at the end of translation by <b>puromycin.</b> Alternatively the protein and its gene can be co-localised by compartmentalisation in living cells or emulsion droplets. The gene sequences isolated are then amplified by PCR or by transformed host bacteria. Either the single best sequence, or a pool of sequences can be used as the template for the next round of mutagenesis. The repeated cycles of Diversification-Selection-Amplification generate protein variants adapted to the applied selection pressures.|$|E
2500|$|Additionally, LepA has {{an effect}} on peptide bond formation. [...] Through various studies in which {{functional}} derivatives of ribosomes were mixed with <b>puromycin</b> (an analog of the 3' end of an aa-tRNA) it was determined that adding LepA to a post transcriptionally modified ribosome prevents dipeptide formation as it inhibits the binding of aa-tRNA to the A site.|$|E
50|$|<b>Puromycin</b> {{resistance}} in yeast {{can also be}} conferred through expression of the <b>puromycin</b> N-acetyl-transferase (pac) gene. Lethal concentrations of <b>puromycin</b> are much higher for strains of Saccharomyces cerevisiae than mammalian cell lines. Deletion of the gene encoding the multidrug efflux pump Pdr5 sensitizes cells to <b>puromycin.</b>|$|E
50|$|<b>Puromycin</b> {{is poorly}} active on E. coli. Puromycin-resistant transformants are {{selected}} in LB agar medium supplemented with 125 µg/ml of <b>puromycin.</b> But use of <b>puromycin</b> for E. coli selection requires precise pH adjustment and {{also depends on}} which strain is selected. For hassle-free selection and optimum results the use of specially modified <b>puromycin</b> is possible. Plates containing <b>puromycin</b> are stable for 1 month when stored at 4 °C.|$|E
50|$|<b>Puromycin</b> is a {{reversible}} inhibitor of dipeptidyl-peptidase II (serine peptidase) and cytosol alanyl aminopeptidase (metallopeptidase). The {{mechanism of}} inhibition {{is not well}} understood, however <b>puromycin</b> {{can be used to}} distinguish between aminopeptidase M (active) and cytosol alanyl aminopeptidase (inhibited by <b>puromycin).</b>|$|E
50|$|<b>Puromycin</b> {{is used in}} {{cell biology}} as a {{selective}} agent in cell culture systems. It is toxic to prokaryotic and eukaryotic cells. Resistance to <b>puromycin</b> is conferred by the pac gene encoding a <b>puromycin</b> N-acetyl-transferase (PAC) that {{was found in a}} Streptomyces producer strain. <b>Puromycin</b> is soluble in water (50 mg/ml) as colorless solution at 10 mg/ml. <b>Puromycin</b> is stable for one year as solution when stored at -20 °C. The recommended dose as a selection agent in cell cultures is within a range of 1-10 μg/ml, although it can be toxic to eukaryotic cells at concentrations as low as 1 μg/ml. <b>Puromycin</b> acts quickly and can kill up to 99% of nonresistant cells within 2 days.|$|E
50|$|Also of note, <b>puromycin</b> is {{critical}} in mRNA display. In this reaction, a <b>puromycin</b> molecule is chemically attached {{to the end of}} an mRNA template, which is then translated into protein. The <b>puromycin</b> can then form a covalent link to the growing peptide chain allowing the mRNA to be physically linked to its translational product.|$|E
50|$|<b>Puromycin</b> is an {{analogue}} of the 3’ {{end of a}} tyrosyl-tRNA with a part of {{its structure}} mimics a molecule of adenosine, and the other part mimics a molecule of tyrosine. Compared to the cleavable ester bond in a tyrosyl-tRNA, <b>puromycin</b> has a non-hydrolysable amide bond. As a result, <b>puromycin</b> interferes with translation, and causes premature release of translation products.|$|E
50|$|To {{synthesize}} an mRNA-polypeptide fusion, the fused <b>puromycin</b> is not {{the only}} modification to the mRNA template. Oligonucleotides and other spacers need to be recruited along with the <b>puromycin</b> to provide flexibility and proper length for the <b>puromycin</b> to enter the A site. Ideally, the linker between the 3’ end of an mRNA and the <b>puromycin</b> has to be flexible and long enough to allow the <b>puromycin</b> to enter the A site upon translation of the last codon. This enables the efficient production of high-quality, full-length mRNA-polypeptide fusion. Rihe Liu et al. optimized the 3’-puromycin oligonucleotide spacer. They reported that dA25 in combination with a Spacer 9 (Glen Research), and dAdCdCP at the 5’ terminus worked the best for the fusion reaction. They found that linkers longer than 40 nucleotides and shorter than 16 nucleotides showed greatly reduced efficiency of fusion formation. Also, when the sequence rUrUP presented adjacent to the <b>puromycin,</b> fusion did not form efficiently.|$|E
5000|$|S-adenosyl-L-methionine + O-demethylpuromycin [...] S-adenosyl-L-homocysteine + <b>puromycin</b> ...|$|E
50|$|<b>Puromycin</b> is {{selective}} for either prokaryotes or eukaryotes.|$|E
50|$|S. alboniger {{produces}} <b>puromycin,</b> {{a type of}} antibiotic.|$|E
5000|$|All mRNA {{templates}} {{used for}} mRNA display technology have <b>puromycin</b> at their 3’ end. As translation proceeds, ribosome moves along the mRNA template, {{and once it}} reaches the 3’ end of the template, the fused <b>puromycin</b> will enter ribosome’s A site and {{be incorporated into the}} nascent peptide. The mRNA-polypeptide fusion is then released from the ribosome (Figure 1).|$|E
50|$|Thus, the two {{substrates}} of this enzyme are S-adenosyl methionine and O-demethylpuromycin, whereas its two {{products are}} S-adenosylhomocysteine and <b>puromycin.</b>|$|E
5000|$|Experimental {{drugs and}} drug precursors: Parthenolide, <b>Puromycin,</b> Rapamycin, Anisomycin, Thapsigargin, cyclopamine, Thiostrepton, Staurosporine, Mithramycin, Midostaurin, Wortmannin, K252a, Geldanamycin and its derivates: 17-DMAG, 17-AAG ...|$|E
50|$|<b>Puromycin</b> is an {{antibiotic}} {{that is a}} protein synthesis inhibitor by inhibiting translation. Causes premature chain termination during translation {{taking place in the}} ribosome.|$|E
5000|$|Vince lactam {{has been}} {{extensively}} used for the preparation of various carbocyclic nucleosides with medicinal applications in mind, including carbocyclic <b>puromycin</b> (I), carbocyclic Ara-A (II), carbovir (III) and guanine as well as azaguanine carbocyclic derivatives (IV) ...|$|E
50|$|This enzyme {{belongs to}} the family of transferases, {{specifically}} those transferring one-carbon group methyltransferases. The systematic name of this enzyme class is S-adenosyl-L-methionine:O-demethylpuromycin O-methyltransferase. This enzyme is also called O-demethylpuromycin methyltransferase. This enzyme participates in <b>puromycin</b> biosynthesis.|$|E
50|$|Some {{examples}} of exopeptidase inhibitors include amastatin, bestatin (ubenimex), <b>puromycin,</b> 1,10-phenanthroline, D-phenylalanine, ACE inhibitors, DPP-4 inhibitors, and exogenous MMP inhibitors like batimastat and marimastat. Various enkephalinase inhibitors, such as ketalorphan, spinorphin, and tynorphin, are mainly exopeptidase inhibitors.|$|E
50|$|Selected hairpins are cloned {{into the}} vector pLKO1, {{which is a}} {{multipurpose}} plasmid that can be propagated in bacteria, transfected into mammalian cell lines or used for generation of lentiviruses. It contains resistance genes against ampicillin and <b>puromycin.</b>|$|E
50|$|A {{number of}} {{antibiotics}} act by inhibiting translation. These include anisomycin, cycloheximide, chloramphenicol, tetracycline, streptomycin, erythromycin, and <b>puromycin.</b> Prokaryotic ribosomes {{have a different}} structure from that of eukaryotic ribosomes, and thus antibiotics can specifically target bacterial infections without any harm to a eukaryotic host's cells.|$|E
5000|$|... #Caption: Figure 1. mRNA-Polypeptide Fusion Formation. a. Ribosome {{moves along}} the mRNA {{template}} and nascent peptide is being made. When the ribosome reaches the 3’ {{end of the}} template, the fused <b>puromycin</b> will enter the A site of the ribosome. b. The mRNA-polypeptide fusion is released.|$|E
5000|$|<b>Puromycin</b> has a {{structure}} {{similar to that}} of the tyrosinyl aminoacyl-tRNA. Thus, it binds to the ribosomal A site and participates in peptide bond formation, producing peptidyl-puromycin. However, it does not engage in translocation and quickly dissociates from the ribosome, causing a premature termination of polypeptide synthesis.|$|E
50|$|Amastatin, bestatin (ubenimex), and <b>puromycin</b> {{have been}} found to inhibit the enzymatic {{degradation}} of oxytocin, though they also inhibit the degradation of various other peptides, such as vasopressin, met-enkephalin, and dynorphin A. EDTA, L-methionine, o-phenanthroline, and phosphoramidon have also been found to inhibit the enzymatic degradation of oxytocin.|$|E
50|$|Oxytocin {{is known}} to be metabolized by the oxytocinase, leucyl/cystinyl aminopeptidase. Other oxytocinases are also known to exist. Amastatin, bestatin (ubenimex), leupeptin, and <b>puromycin</b> have been found to inhibit the enzymatic {{degradation}} of oxytocin, though they also inhibit the degradation of various other peptides, such as vasopressin, met-enkephalin, and dynorphin A.|$|E
50|$|This {{method is}} an {{adaptation}} of mRNA display technology. PCR DNA is first transcribed to mRNA, and a single-stranded DNA oligonucleotide modified with biotin and <b>puromycin</b> on each end is then hybridized to the 3’-end of the mRNA. The mRNAs are then arrayed on a slide and immobilized by the binding of biotin to streptavidin that is pre-coated on the slide. Cell extract is then dispensed on the slide for in situ translation to take place. When the ribosome reaches the hybridized oligonucleotide, it stalls and incorporates the <b>puromycin</b> molecule to the nascent polypeptide chain, thereby attaching the newly synthesized protein to the microarray via the DNA oligonucleotide. A pure protein array is obtained after the mRNA is digested with RNase. The protein spots generated by this method are very sharply defined and can be produced at a high density.|$|E
50|$|Additionally, LepA has {{an effect}} on peptide bond formation. Through various studies in which {{functional}} derivatives of ribosomes were mixed with <b>puromycin</b> (an analog of the 3' end of an aa-tRNA) it was determined that adding LepA to a post transcriptionally modified ribosome prevents dipeptide formation as it inhibits the binding of aa-tRNA to the A site.|$|E
50|$|Protein {{synthesis}} inhibitors are a {{class of}} antibiotics, which prevent the production of new proteins by inhibiting the cell’s gene expression ("Protein synthesis inhibitors", PSI). They generally operate at the ribosomal level through various mechanisms that prevent the ribosome from completing translation (Vazquez, 1967). Protein synthesis inhibitors that work in prokaryotic cells are often used as clinically prescribed antibiotics, while those that act of eukaryotic cells have been adapted for research purposes. In research, commonly used PSI’s include anisomycin, cycloheximide, and <b>puromycin</b> - although the use of <b>puromycin</b> has stopped recently because of its toxic qualities and numerous side effects (Burka, Ballas, & Sabesin, 1975). Anisomycin has relatively high effectiveness in inhibiting protein synthesis and has a large effective time window (Villers, Godaux, & Ris, 2012). Cycloheximide is frequently used in acute studies, because of its high level of inhibition and ease of reversibility (Villers, Godaux, & Ris, 2012).|$|E
50|$|<b>Puromycin</b> is an aminonucleoside antibiotic, {{derived from}} the Streptomyces alboniger bacterium, that causes {{premature}} chain termination during translation {{taking place in the}} ribosome. Part of the molecule resembles the 3' end of the aminoacylated tRNA. It enters the A site and transfers to the growing chain, causing the formation of a puromycylated nascent chain and premature chain release. The exact mechanism of action is unknown at this time but the 3' position contains an amide linkage instead of the normal ester linkage of tRNA. That makes the molecule much more resistant to hydrolysis and stops the ribosome.|$|E
5000|$|... mRNA {{display is}} a display {{technique}} used for in vitro protein, and/or peptide evolution to create molecules that {{can bind to}} a desired target. The process results in translated peptides or proteins {{that are associated with}} their mRNA progenitor via a <b>puromycin</b> linkage. The complex then binds to an immobilized target in a selection step (affinity chromatography). The mRNA-protein fusions that bind well are then reverse transcribed to cDNA and their sequence amplified via a polymerase chain reaction. The result is a nucleotide sequence that encodes a peptide with high affinity for the molecule of interest.|$|E
50|$|When {{functional}} proteins {{have been}} isolated, {{it is necessary}} that their genes are too, therefore a genotype-phenotype link is required. This can be covalent, such as mRNA display where the mRNA gene is linked to the protein at the end of translation by <b>puromycin.</b> Alternatively the protein and its gene can be co-localised by compartmentalisation in living cells or emulsion droplets. The gene sequences isolated are then amplified by PCR or by transformed host bacteria. Either the single best sequence, or a pool of sequences can be used as the template for the next round of mutagenesis. The repeated cycles of Diversification-Selection-Amplification generate protein variants adapted to the applied selection pressures.|$|E
50|$|While {{studying}} {{the effect of}} proteoglycan composition on nephritic permselectivity, {{it was noted that}} <b>puromycin</b> treatment of human glomerular endothelial cells (HGEC) altered the sulfation level of GAG chains on proteoglycans such as perlecan, which in turn caused a decrease in the stability of the GAG chains. The core protein mRNA levels of proteoglycans were not affected, thus the decrease in GAG chains was as a result of some other factor, which in this case {{turned out to be a}} decrease in expression of sulfate transferase enzymes, which play a key role in GAG biosynthesis. It seems that there may be some overlap in diseases stemming from loss of heparan sulfate proteoglycan expression and loss of enzymes involved in heparan sulfate biosynthesis.|$|E
50|$|Once the mRNA {{library is}} generated, {{it will be}} Urea-PAGE {{purified}} and ligated using T4 DNA ligase to the DNA spacer linker containing <b>puromycin</b> at the 3’ end. In this ligation step, a piece of mRNA is ligated with a single stranded DNA with the help from T4 DNA ligase. This is not a standard T4 DNA ligase ligation reaction, where two pieces of double stranded DNA are ligated together. To increase the yield of this special ligation, a single stranded DNA splint {{may be used to}} aid the ligation reaction. The 5’ terminus of the splint is designed to be complementary to the 3’ end of the mRNA, and the 3’ terminus of the splint is designed to be complementary to the 5’ end of the DNA spacer linker, which usually consists of poly dA nucleotides (Figure 2).|$|E
